JPS54151134A - Antitumorigenic agent - Google Patents

Antitumorigenic agent

Info

Publication number
JPS54151134A
JPS54151134A JP5975978A JP5975978A JPS54151134A JP S54151134 A JPS54151134 A JP S54151134A JP 5975978 A JP5975978 A JP 5975978A JP 5975978 A JP5975978 A JP 5975978A JP S54151134 A JPS54151134 A JP S54151134A
Authority
JP
Japan
Prior art keywords
antitumorigenic
agent
oxide
antitumorigenic agent
nitrofurylvinylthiazole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP5975978A
Other languages
Japanese (ja)
Other versions
JPS6136493B2 (en
Inventor
Satoshi Enomoto
Daisaku Inmaru
Yoshiaki Osaka
Takao Kawasaki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kureha Corp
Original Assignee
Kureha Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kureha Corp filed Critical Kureha Corp
Priority to JP5975978A priority Critical patent/JPS54151134A/en
Priority to CH454979A priority patent/CH640850A5/en
Priority to IT22723/79A priority patent/IT1114243B/en
Priority to FR7912549A priority patent/FR2426052A1/en
Priority to GB7917473A priority patent/GB2021111B/en
Priority to DE2920247A priority patent/DE2920247C2/en
Publication of JPS54151134A publication Critical patent/JPS54151134A/en
Publication of JPS6136493B2 publication Critical patent/JPS6136493B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PURPOSE: An antitumorigenic agent that contains nitrofurylvinylthiazole-N-oxide as the effective component, thus showing remarkable and selective antitumorigenic effect and permitting safe and long-term administration against cancers of digestive tracts as stomach, esophague, recturm, etc.
CONSTITUTION: Nitrofurylvinylthiazole-N-oxide of the formula (R1 and R2 are H, 1W4C alkyl, lower alkoxycarbonyl, or R1 and R2 incorporate to form cycloalkenyl) as 2-(5-nitro-2-furylvinyl)-4,5-dimethylthiazole-N-oxide is used as the effective component to prepare oral pills or ointment, which is administered as antitumorigenic agent. The does is 0.05W100 mg/kg, preferably 0.1W20 mg/kg daily. This antitumorigenic agent is higher in the inhibition rate of melanoma cell multiplication. It also is expected to be safe antitumorigenic agent that can be added to the solution for washing bladder in the treatment of bladder cancer.
COPYRIGHT: (C)1979,JPO&Japio
JP5975978A 1978-05-19 1978-05-19 Antitumorigenic agent Granted JPS54151134A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP5975978A JPS54151134A (en) 1978-05-19 1978-05-19 Antitumorigenic agent
CH454979A CH640850A5 (en) 1978-05-19 1979-05-16 NITROFURYLVINYLTHIAZOLE-N-OXIDE COMPOUNDS AS AN ANTITUARY AGENT.
IT22723/79A IT1114243B (en) 1978-05-19 1979-05-16 ANTI-TUMORAL AGENT BASED ON THIAZOLIC DERIVATIVES
FR7912549A FR2426052A1 (en) 1978-05-19 1979-05-17 NITROFURYL-VINYLENIC COMPOUNDS, NEW ANTITUMOR DRUGS
GB7917473A GB2021111B (en) 1978-05-19 1979-05-18 Nitro - furyl - vinylene - thiazole n-oxides as antitumour agents
DE2920247A DE2920247C2 (en) 1978-05-19 1979-05-18 Use of a nitrofuryl-vinylene-thiazole-N-oxide compound for the preparation of anti-tumor agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5975978A JPS54151134A (en) 1978-05-19 1978-05-19 Antitumorigenic agent

Publications (2)

Publication Number Publication Date
JPS54151134A true JPS54151134A (en) 1979-11-28
JPS6136493B2 JPS6136493B2 (en) 1986-08-19

Family

ID=13122504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP5975978A Granted JPS54151134A (en) 1978-05-19 1978-05-19 Antitumorigenic agent

Country Status (6)

Country Link
JP (1) JPS54151134A (en)
CH (1) CH640850A5 (en)
DE (1) DE2920247C2 (en)
FR (1) FR2426052A1 (en)
GB (1) GB2021111B (en)
IT (1) IT1114243B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894071B2 (en) 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0441034Y2 (en) * 1986-04-23 1992-09-25
JPH0413498U (en) * 1990-05-24 1992-02-03
CA2646222C (en) * 2006-03-16 2016-07-05 Women And Infants Hospital Of Rhode Island, Inc. Nitrofuran compounds for the treatment of cancer and angiogenesis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1545606A1 (en) * 1965-07-29 1969-08-07 Boehringer Mannheim Gmbh Process for the preparation of new 5-nitrofuran derivatives
JPS5239033B1 (en) * 1971-05-04 1977-10-03
JPS5239033A (en) * 1975-09-22 1977-03-26 Meidensha Electric Mfg Co Ltd An engine controlling device
GB2079568A (en) * 1980-07-02 1982-01-20 Hewlett Packard Co Data compression apparatus and method
JPS5742662A (en) * 1980-08-29 1982-03-10 Chugai Pharmaceut Co Ltd Benzoic acid amide derivative

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ARZNEIM.FORSCH=1967 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6894071B2 (en) 2001-11-01 2005-05-17 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US7977369B2 (en) 2001-11-01 2011-07-12 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US8563592B2 (en) 2001-11-01 2013-10-22 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods
US8648108B2 (en) 2001-11-01 2014-02-11 Spectrum Pharmaceuticals, Inc. Medical compositions for intravesical treatment of bladder cancer
US9295666B2 (en) 2001-11-01 2016-03-29 Spectrum Pharmaceuticals, Inc. Bladder cancer treatment and methods

Also Published As

Publication number Publication date
IT7922723A0 (en) 1979-05-16
DE2920247C2 (en) 1985-09-19
FR2426052B1 (en) 1983-04-08
FR2426052A1 (en) 1979-12-14
IT1114243B (en) 1986-01-27
JPS6136493B2 (en) 1986-08-19
DE2920247A1 (en) 1979-11-22
GB2021111B (en) 1982-11-03
GB2021111A (en) 1979-11-28
CH640850A5 (en) 1984-01-31

Similar Documents

Publication Publication Date Title
JPS54151134A (en) Antitumorigenic agent
MY102003A (en) Novel derivatives of 4, 5-dihydrooxazoles, a process for their preparation, and their use.
KR920702225A (en) Pharmaceutical composition
JPS52108028A (en) Remedies for dysacousis
DE3365900D1 (en) Nitrosourea derivatives, process for their preparation and pharmaceutical compositions containing them
JPS5630917A (en) Preventive and remedy for hepatitis
KR970704723A (en) Dihydrobenzofuran and related compounds useful as anti-inflammatory agents (DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS)
JPS5793913A (en) Enhancing agent for spermous vital power
EP0093497A3 (en) Anthelmintic treatment
JPS57158719A (en) Rectal administration pharmaceutical
JPS5435214A (en) Remedy and prophylaxis of scours of calf
JPS54132239A (en) Anti-tumor agent
JPS5536454A (en) Novel immunosuppressive agent
FR2224152A1 (en) Thiazolotriazolyl phosphorothioates as anthelmintics - combining good anthelmintic activity with low toxicity to warm-blooded animals
JPS5750916A (en) Carcinostatic agent
JPS5695114A (en) Carcinostatic agent
JPS5675427A (en) Antiarteriosclerotic agent containing procainamide hydrochloride
JPS5610114A (en) Novel analgesic and anti-inflammatory agent
JPS56166116A (en) Carcinostatic agent
JPS5569510A (en) Carcinostatic agent
JPS5498339A (en) Carcinostatic agent
JPS5735514A (en) Blood sugar level depressing agent
GB1289039A (en)
JPS57175119A (en) Agent for removing cancer
JPS54105237A (en) Analgesic agent containing nalorphine-6-glucuronide